Loading...
Market
Story
Johnson & Johnson's Rybrevant Approved by FDA as Second-Line Treatment for EGFR-Mutated Advanced Lung Cancer
Sep 20, 2024, 12:12 PM
Johnson & Johnson's Rybrevant (amivantamab-vmjw) plus standard of care has received FDA approval for use as a second-line treatment for EGFR-mutated advanced lung cancer (NSCLC). This approval marks a significant milestone in oncology as it is the first targeted regimen to reduce the risk of disease progression by more than half. Johnson & Johnson aims to achieve $5 billion in sales for Rybrevant.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Fewer than 30 countries • 25%
30 to 60 countries • 25%
60 to 90 countries • 25%
More than 90 countries • 25%